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Abstract
Background: The hypocholesterolemic effects of lactic acid bacteria (LAB) have now become an area of great
interest and controversy for many scientists. In this study, we evaluated the effects of Lactobacillus plantarum 9-41-
A and Lactobacillus fermentum M1-16 on body weight, lipid metabolism and intestinal microflora of rats fed a high-
cholesterol diet.
Methods: Forty rats were assigned to four groups and fed either a normal or a high-cholesterol diet. The LAB-
treated groups received the high-cholesterol diet supplemented with Lactobacillus plantarum 9-41-A or
Lactobacillus fermentum M1-16. The rats were sacrificed after a 6-week feeding period. Body weights, visceral organ
and fat pad weights, serum and liver cholesterol and lipid levels, and fecal cholesterol and bile acid concentrations
were measured. Liver lipid deposition and adipocyte size were evaluated histologically.
Results: Compared with rats fed a high-cholesterol diet but without LAB supplementation, serum total cholesterol,
low-density lipoprotein cholesterol and triglycerides levels were significantly decreased in LAB-treated rats (p <
0.05), with no significant change in high-density lipoprotein cholesterol levels. Hepatic cholesterol and triglyceride
levels and liver lipid deposition were significantly decreased in the LAB-treated groups (p < 0.05). Accordingly, both
fecal cholesterol and bile acids levels were significantly increased after LAB administration (p < 0.05). Intestinal
Lactobacillus and Bifidobacterium colonies were increased while Escherichia coli colonies were decreased in the LAB-
treated groups. Fecal water content was higher in the LAB-treated groups. Compared with rats fed a high-
cholesterol diet, administration of Lactobacillus plantarum 9-41-A resulted in decreases in the body weight gain,
liver and fat pad weight, and adipocytes size (p < 0.05).
Conclusions: This study suggests that LAB supplementation has hypocholesterolemic effects in rats fed a high-
cholesterol diet. The ability to lower serum cholesterol varies among LAB strains. Our strains might be able to
improve the intestinal microbial balance and potentially improve intestinal transit time. Although the mechanism is
largely unknown, L. plantarum 9-41-A may play a role in fat metabolism.
Background
Elevated serum cholesterol level is widely recognized as a
contributory risk factor for the development of cardiovas-
cular diseases (CVD) such as atherosclerosis, coronary
heart disease and stroke. The World Health Organization
(WHO) has predicted that by 2030, CVD will remain the
leading causes of death and affect approximately 23.6
million people globally [1]. It has been reported that even
a 1% reduction in serum cholesterol could reduce the
risk of coronary heart disease by 2-3% [2]. Current drug
therapies, with their high relative costs and associated
side effects, are not viewed to be the optimal long-term
answers. The development of alternative management
strategies for the treatment of hypercholesterolemia is
necessary, especially for people with borderline choles-
terol levels.
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lesterolemic effects of fermented milk ingested by the
Massai tribes people, the relationship between lactic acid
bacteria (LAB) and the serum cholesterol has become a
focus of great interest. Studies evaluating this relationship
have found that lactobacilli or bifidobacteria can exhibit
hypocholesterolemic properties in animal models [4-6]
and in humans [7-10]. Several hypotheses have been
proposed to explain these findings: (1) consumption of
cholesterol by intestinal bacteria, thus reducing the
amount of cholesterol available for absorption [11,12]; (2)
cholesterol may be bound to the bacterial cellular surface
[13] or incorporated into the bacterial cellular mem-
branes [14] or converted into coprostanol by cholesterol
reductase, which is producedb ys t r a i n so flactobacilli
[15]; (3) inhibition of micelle formation by certain pro-
biotic strains [16]; (4) short-chain fatty acids produced
upon selective fermentation of food by intestinal bacterial
microflora may lower plasma cholesterol levels [17]; and
(5) some bacterial species excrete bile salt hydrolase,
leading to increased bile excretion in feces [18]. However,
other reports are contradictory and fail to show hypocho-
lesterolemic effects of probiotics [19,20]. Consequently,
this area remains controversial. Therefore, more informa-
tion is required to strengthen the proposed hypotheses
and improve our undetstanding of how bacteria affect
cholesterol metabolism, which might lead to more appro-
priate use of probiotics.
To date, most investigations on the effects of LAB on
cholesterol have focused on species isolated from dairy pro-
ducts or feces of infants. In our previous work, we isolated
several strains of lactobacilli from the stool of healthy adult
Chinese volunteers. In in vitro screening-experiments,
more than 30 strains of the bacteria demostrated a choles-
terol-lowering activity. Among these strains, two strains, 9-
41A and M1-16 expressed the highest cholesterol-removing
abilities in their growth medium and were selected for the
present study. We aimed to: 1) examine the effects of these
two strains on cholesterol levels, body weight and intestinal
microflora in rats; and 2) explore the possible mechanisms
by which these strains might exert their hypocholesterole-
mic effects.
Methods
Preparation of bacterial cultures
The two strains used in this study, Lactobacillus plan-
tarum 9-41-A [GenBank accession no. HQ424577] and
Lactobacillus fermentum M1-16 [GenBank accession no.
HQ423153], were two local strains isolated from the
feces of healthy adults and stored at -80°C. They showed
good survival at low pH, tolerance to high bile concentra-
tion, and abilities to lower cholesterol in in vitro trials.
After recovery at 35°C for 30 minutes in a biochemical
incubator, the two strains were separately inoculated into
MRS liquid broth and placed in an anaerobic workstation
at 35°C for 24 hours. The strains were harvested by cen-
trifugation at 2000 × g for 20 minutes, washed twice with
normal saline (0.9% NaCl), and resuspended at 2 × 10
9
CFU/mL in sterile normal saline. Subsequently, 2 mL of
the solution was administered intragastrically to the rats
daily.
Animal groups and diets
Forty male Sprague-Dawley rats (conventional clean ani-
mal grade), aged 5 weeks and weighing 120.2 ± 4.5 grams,
were purchased from Slaccas Laboratory Animal Ltd.
(Shanghai, China). All rats were housed individually in
metal cages under a controlled room temperatures (20 ±
2°C) and humidity (50 ± 5%), and maintained on a con-
stant 12-hour/12-hour light/dark cycle. The care and use
of the animals followed our institutional and national
guidelines and all experimental procedures involving
animals were approved by the Ethics Committee of the
Central South University.
A 1-week adaptive period on a normal diet containing
32% (weight/weight) protein, 5% fat, 2% fiber, 1.8% cal-
cium, 1.2% phosphorus, and a nitrogen-free extract as the
remainder (Commercial Chow, Kangqiao Inc., Beijing,
China) was instituted [21]. The 40 rats were randomly
selected and assigned to four groups of 10 rats each. The
initial average body weight was similar among the four
groups. The four groups were assigned diets according to
the following regimen: (1) control group, normal diet; (2)
model group, high-cholesterol diet; (3) L.9-41-A group,
high-cholesterol diet + L. plantarum 9-41-A; (4) L.M1-16
group, high-cholesterol diet + L. fermentum M1-16. The
high-cholesterol diet contained 1% (weight/weight) choles-
t e r o l ,1 0 %l a r d ,1 0 %s u c r o s e ,0 . 3 %s o d i u mc h o l a t e ,0 . 2 %
propylthiouracil and a commercial chow mix (Aoboxing
Biotech Co., Ltd., Beijing, China) [21]. Rats had free access
to water and their group-specific diet. The L.9-41-A group
and L.M1-16 groups received 2 mL (10
9 CFU/mL) daily of
L. plantarum 9-41-A and L. fermentum M1-16 solutions
respectively, intragastrically for the 6-week study period.
Control and model groups received an equivalent amount
of normal saline. Body weight was recorded weekly and
food consumption was monitored daily. After the feeding
period, the rats were fasted for 12 hours and euthanized.
The weight of visceral organs (liver, spleen, and kidney)
and mesenteric, perirenal, and epididymal white adipose
tissues (WAT) were measured.
Assay for serum lipids
Blood sample (4 mL) was obtained from the celiac vein
and transferred to nonheparinized vacuum collection
tubes. Tubes were initially held stationary at 0°C for 30
minutes, and then centrifuged at 2000 × g for 15 minutes
at 4°C. Serum total cholesterol (TCH), high-density
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cholesterol (LDL-C) and triglycerides (TG) were measured
with commercial kits (Daiichi Chemicals Co., Ltd, Tokyo,
Japan) and a chemical analyzer 7020 (Hitachi, Tokyo,
Japan). Atherogenic indexes (TCH/HDL-C and TG/HDL-
C ratios) were then calculated.
Assay for liver TCH, TG and fecal sterol contents
After euthanasia, rat livers were removed, rinsed with
physiological saline solution, blotted dry and weighed.
The middle lobe was standardized as the sampling
region. A portion of the tissues was sectioned and
soaked in 10% (volume/volume) formaldehyde for 24
hours for subsequent staining, with the remainder
stored at -80°C for further testing. Liver TCH and TG
contents were determined after homogenization with
Folch solution(chloroform/methanol ratio = 2:1) [22].
Fecal droppings were collected during the last 3 days of
life, and fecal neutral and acidic sterols were extracted
using Tokunaga’ s method [23]. A sample (1 gram) of wet
feces was extracted with 10 mL of acetone/ethanol (1:1)
mixture. After drying, 3 mL of diethyl ether and 3 mL of
1 N NaOH solution were added to separate the neutral
and acidic sterols. The ether phase containing neutral ster-
ols was dried and dissolved in 3 mL of acetic acid for cho-
lesterol measurement. The NaOH solution phase was used
for bile acid measurement with a commercial kit (Daiichi
Chemicals Co., Ltd., Tokyo, Japan).
Histopathology of liver and adipocytes in the WAT
Liver samples from each rat were fixed in 10% (volume/
volume) formaldehyde, embedded in paraffin and stained
with hematoxylin-eosin (HE). The perirenal WAT was
removed and embedded after delipidation. After fixation
in 20% (v/v) formalin/1% glutaraldehyde, 3-mm tissue
sections were created and stained with HE [24]. We took
three samples from liver and the WAT of each rat, and
made three replicates for each sample. All histologic sec-
tion was observed under 5 high-power fields. The classifi-
cation and degree of fatty deposition used was as follows
[22]: +, mild fatty degeneration, fatty hepatocytes occupy
30%-50% of the hepatic parenchyma; ++, moderate fatty
degeneration, fatty hepatocytes occupy 50%-75% of the
hepatic parenchyma; +++, severe fatty degeneration fatty
hepatocytes occupy > 75% of the hepatic parenchyma.
The number and size of the adipocytes in the WAT were
measured using an ocular micrometer (YanFeng Instru-
ment Co., Ltd., Hengyang, China).
Analysis of intestinal microflora
The cecum and a portion of the adjacent colon tissue of
each rat were removed and placed in capped sterile
tubes. After transfer to a laminar flow cabinet, 1 gram
of each sample was transferred to a tube with 9 mL of
0.9% NaCl solution and homogenized by vortexing for
10 minutes. Ten fold serial dilutions of each sample
were performed to obtain 10-μL concentrations, which
were plated with selective culture medium in triplicate.
EMB agar (pH 7.1 ± 0.2) was used for Escherichia coli
(E. coli), TCH sodium azide agar (pH 7.3 ± 0.1) was
used for Enterococcus faecalis, LBS agar (pH 5.5 ± 0.2)
was used for LAB, and BS agar (pH 7.2 ± 0.1) was used
for bifidobacteria. All media were obtained from Hope
Bio-Technology (Qingdao, China). Aerobic plates were
placed in a biochemistry incubator at 37°C for 24 hours
while anaerobic plates incubated at 37°C for 48 hours.
The colonies counted after incubation represented the
numbers of E. coli, Enterococcus faecalis, Lactobacillus,
and Bifidobacterium.
Measurement of fecal water content
In the middle of the third and sixth weeks, rat feces were
collected, weighed and dried at 80°C in a DZF-6050
vacuum drying oven (MingKe Instrument Co., Ltd.,
Shengzhen, China). until a constant weight was achieved
within 24 hours, and then reweighed. Fecal water content
was calculated as follows: fecal water content (%) =
[(weight before drying-weight after drying)/weight before
drying] × 100.
Statistical Analysis
All data was analysed in duplicate with SPSS 15.0 software
(SPSS Inc., Chicago, IL, USA). One-way analysis of var-
iance (ANOVA) with Duncan’s multiple range test was
performed to compare any significant differences (p <
0.05) in the variables between groups. Experimental data
were presented as the mean ± standard deviations (SD) of
the mean. Rank and frequency data were analyzed by a
nonparametric test.
Results
Growth of rats
All the rats appeared healthy throughout the feeding per-
iod. There were no significant differences in total food
intake (p > 0.05) among the four groups. All rats fed the
high-cholesterol diet exhibited higher (p < 0.05) body
weight gains and food efficiencies than control rats
(Table 1). The L.9-41-A group showed less weight gain (a
reduction of 13.3%, p < 0.05) and food efficiency than the
model group while the L.M1-16 group had no obvious
difference in weight gain and food efficiency compared
with the model group.
Blood lipid analyses
S e r u mT C H ,H D L - C ,L D L - Ca n dT Gl e v e l si nt h ef o u r
groups were shown in Figure 1A. The TCH and LDL-C
levels differed significantly among the four groups. Rats
fed a high-cholesterol diet had greatly increased levels of
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fed the normal diet (p < 0.05). Compared with the con-
trol group, the model group showed a 63.7% increase in
TCH (254.89 ± 22.47 vs.1 5 5 . 7 2±1 5 . 9 6m g / d L ,p<
0.05), a 176.6% increase in LDL-C (155.16 ± 22.43 vs.
56.10 ± 14.03 mg/dl, p < 0.05) and a 60.3% increase in
TG (128.31 ± 12.05 vs. 80.03 ± 12.39 mg/dL, p < 0.05).
The two LAB strains displayed in vivo hypocholesterole-
mic abilities. Compared with the model group, the L.9-
4 1 - Ag r o u pa c h i e v e dam a x i m a lT C Hr e d u c t i o no f
25.3% (190.36 ± 20.67 vs. 254.89 ± 22.47 mg/dL, p <
0.05) and an LDL-C reduction of 32.9% (104.13 ± 16.11
vs. 155.16 ± 22.43 mg/dL, p < 0.05) while the L.M1-16
group achieved a TCH reduction of 12.5% (223.12 ±
16.84 vs. 254.89 ± 22.47 mg/dL, p < 0.05) and an LDL-
C reduction of 17.3% (128.28 ± 15.43 mg/dL vs. 155.16
± 22.43 mg/dL, p < 0.05). The control group showed
the highest HDL-C concentration, and the two LAB
strains did not demonstrate obvious influences on the
HDL-C levels. However, serum TG level was signifi-
cantly lower in the LAB-treated groups than in the
model group. Specifically, the L.9-41-A group displayed
a TG reduction of 16.9% (106.65 ± 12.58 vs.1 2 8 . 3 1±
12.05 mg/dL, p < 0.05) while the L.M1-16 group dis-
played a TG reduction of 15.7% (108.12 ± 13.35 vs.
128.31 ± 12.05 mg/dL, p < 0.05), while the two LAB-
t r e a t e dg r o u p ss h o w e dn os i g n i f i c a n td i f f e r e n c e( p>
0.05). The control group had the lowest (p < 0.05)
atherogenic indexes among all four groups. Compared
with the model group, the atherogenic indexes were sig-
nificantly lower in the L.9-41-A group (TCH/HDL-C
ratio, 2.95 ± 0.54 vs.4 . 0 8±0 . 5 7 ;T G / H D L - Cr a t i o ,1 . 6 5
±0 . 3 0vs.2 . 0 6±0 . 2 9 )a n dt h eL.M1-16 group (TCH/
HDL-C ratio 3.40 ± 0.36 vs. 4.08 ± 0.57; TG/HDL-C
ratio, 1.66 ± 0.32 vs. 2.06 ± 0.29) (Figure 1B). Between
the two LAB-treated groups, the L.9-41-A group had
lower (p < 0.05) TCH/HDL-C ratio than the L.M1-16
group, and the TG/HDL-C ratio was similar between
the two groups (p > 0.05).
Liver and fecal lipid analyses
Liver and fecal lipid contents were shown in Figures 1C
and 1D. The control group displayed the lowest levels of
both hepatic TCH (10.69 ± 1.54 mg/g) and TG (17.90 ±
2.67 mg/g). The L.9-41-A and L.M1-16 groups showed
no obvious differences in both hepatic TCH and TG
levels, but they all had lower concentrations (p < 0.05)
than the model group (TCH, 14.70 ± 1.42 and 14.82 ±
1.31 vs. 18.93 ± 1.59 mg/g, respectively; TG, 25.82 ±
2.50 and 26.44 ± 2.68 vs. 33.14 ± 2.19 mg/g, respec-
tively). The high-cholesterol diet increased the fecal
excretion of cholesterol and bile acids. Compared with
the model group, the L.9-41-A group displayed a 39.2%
increase in fecal cholesterol (39.94 ± 2.39 vs. 28.68 ±
3.48 mg/day, p < 0.05) and a 40% increase in fecal bile
acids (22.70 ± 2.29 vs. 16.21 ± 3.68 mg/day, p < 0.05)
while the L.M1-16 group showed a 30.2% increase in
fecal cholesterol (37.33 ± 2.92 vs. 28.68 ± 3.48 mg/day,
p < 0.05) and a 19% increase in fecal bile acids (19.29 ±
3.41 vs. 16.21 ± 3.68 mg/day, p < 0.05). The two LAB-
treated groups had similar amount of fecal cholesterol
content but the L.9-41-A group had more fecal bile
acids (p < 0.05) than the L.M1-16 group.
Visceral organ and WAT weight
Visceral organ and WAT weight were shown in Table 2.
The rats in the control group had the lowest liver and
WAT weight. The rats in the L.9-41-A and L.M1-16
groups had significantly lower liver weight than the rats
in the model group (p < 0.05). There were no significant
differences in the weight of spleens or kidneys among
the four groups. Control group had the lowest WAT
weight in all four gourps. Compared with the model
group, WAT weights extracted from the rats of L.9-41-
A group was dramatically reduced (p < 0.05), while the
L.M1-16 group rats only showed a reduction in the
weight of the epididymal fat pad (p < 0.05). Rats of the
L.9-41-A group also showed smaller weight of mesen-
teric and perirenal fat pad than rats of the L.M1-16
group.
Hepatic lipid deposition in the four groups
The LAB-treated rats exhibited an overall normal gross
liver appearance. Liver lipid deposition was evaluated in
a semiquantitative manner. As shown in Figure 2, no
fatty vacuolization was found in the control group. The
Table 1 Body weight gain, total food intake, and food efficiency (n = 10 per group) after 6 weeks
Group Body weight gain(g) Total food intake(g) Food efficiency*(%)
Control 144.6
c ± 10.2 879.9
a ± 18.9 16.4
c ± 1.1
Model 177.0
a ± 8.8 875.1
a ± 25.6 20.2
a ± 1.0
L. 9-41-A 153.5
b ± 8.2 881.3
a ± 21.2 17.4
b ± 1.0
L.M1-16 172.4
a ± 10.4 883.9
a ± 22.7 19.50
a ± 1.0
Control group: normal diet; model group: high-cholesterol diet; L.9-41-A group: high-cholesterol diet + L. plantarum 9-41-A; L.M1-16 group: high-cholesterol diet+
L. fermentum M1-16.
*Food efficiency (%) = (body weight gain/food intake) × 100.
The data are shown as the mean ± standard deviation
a,b,c Mean values within a column with different superscript letters differ significantly (p < 0.05, n = 10).
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of vacuolization and increased lipid deposition in the
cytoplasm, which was obviously lower in the L.9-41-A
and L.M1-16 groups. Hepatocyte steatosis was alleviated
in the control, L.9-41-A and L.M1-16 groups compared
with the model group by a non-parametric test (c2=
24.118, p < 0.001) (Figure 2 and Table 3).
Effects of L. plantarum 9-41-A and L. fermentum M1-16 on
adipocyte numbers and sizes in the WAT
Morphometric analyses of the WAT were shown in
Figure 3 and Table 4. The perirenal WAT in the
model group rats had approximately half the numbers
of adipocytes observed in the control and L.9-41-A
groups. The L.M1-16 group had more adipocytes
under each field of view than the model group, but the
number was less than the control and L.9-41-A groups
(p < 0.05). The average adipocyte size in the model
group was significantly (p < 0.05) larger than that in
the control and L.9-41-A groups. The L.M1-16 group
showed a smaller adipocyte size than that in the model
group, although this was not significant.
Microbial populations
Figure 4 showed the effects of the different diets and
LAB supplementation on the rat intestinal bacteria flora.
The model group showed the highest (p < 0.05) total
E. coli content (5.7 log CFU/g), followed by the L.9-41-
A group (4.9 log CFU/g), L.M1-16 group (4.8 log CFU/
g) and control group (4.0 log CFU/g). There were no
significant differences in the Enterococcus faecalis colo-
nies among the four groups. Compared with the model
group (6.5 log CFU/g for Lactobacillus and 7.2 log
CFU/g for Bifidobacterium), significant increases (p <
Table 2 Effects of L. plantarum 9-41-A and L. fermentum
M1-16 on organ and WAT weight in rats
Weight index(g) Group (mean ± SD, n = 10 per group)
Control Model L.9-41-A L.M1-16
Liver 9.5
c ± 0.8 12.5
a ± 1.2 10.3
b ± 1.1 10.7
b ± 1.4
Spleen 0.6 ± 0.1 0.6 ± 0.1 0.6 ± 0.1 0.6 ± 0.1
Kidney 1.7 ± 0.1 1.7 ± 0.1 1.7 ± 0.1 1.7 ± 0.1
MFP 4.0
b ± 0.4 5.0
a ± 0.8 4.1
b ± 0.9 4.8
a ± 0.6
PFP 3.5
c ± 0.6 6.2
a ± 1.8 4.9
b ± 1.0 6.1
a ± 1.0
EFP 4.0
c ± 0.4 5.4
a ± 1.3 4.5
b ± 1.0 4.9
b ± 1.2
Control group: normal diet; model group: high-cholesterol diet; L.9-41-A
group: high-cholesterol diet + L. plantarum 9-41-A; L.M1-16 group: high-
cholesterol diet+ L. fermentum M1-16.
MFP, mesenteric fat pad; PFP, perirenal fat pad; EFPs, epididymal fat pad
The data are shown as the mean ± standard deviation
a,b,c Mean values within
a row with different superscript letters differ significantly (p < 0.05, n = 10).
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Figure 1 Effects of the two LAB strains on lipid metabolism in
rats fed a high-cholesterol diet. A: Serum TCH, HDL-C, LDL-C and
TG contents; B: Atherogenic indexes of the rats; C: Liver TCH and
TG contents of the rats; D: Fecal total cholesterol and bile acid
content. The data are shown as the mean ± standard deviation (n =
10),
a,b,c,d Mean values in each panel with different superscript
letters differ significantly (p < 0.05).
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were observed in the cecal samples from the control
group (7.5 log CFU/g for Lactobacillus and 8.1 log
CFU/g for Bifidobacterium), L.9-41-A group (8.1 log
CFU/g for Lactobacillus and 8.0 log CFU/g for Bifido-
bacterium)a n dL.M1-16 group (7.9 log CFU/g for Lac-
tobacillus and 8.0 log CFU/g for Bifidobacterium).
There were no significant differences (p > 0.05) in the
number of Lactobacillus and Bifidobacterium colonies
between the L.9-41-A group and the L.M1-16 group,
and the two groups had more Lactobacillus colonies
than the control group (p < 0.05).
Fecal water content
Fecal water content data collected in the middle of the
third and sixth weeks was shown in Figure 5. The fecal
water content showed no significant differences in the
third week among the four groups (range, 50-55%, p >
0.05). However, at the end of the feeding period, there
was a higher fecal moisture content in the L.9-41-A
(63%) and L.M1-16 (62%) groups than in the control
(52%) and model (53%) groups.
Discussion
Elevated serum cholesterol and LDL-C are strongly asso-
ciated with increasing CVD risks. Recent reports demon-
strating the hypocholesterolemic effects of probiotics
have led to increased interest in this treatment modality,
w h i c hi sl e s se x p e n s i v ea n d could be considered a “nat-
ural health remedy”. We tested two fecal-derived strains
of LAB and found the hypocholesterolemic effects
Figure 2 Histology of liver steatosis in the four groups. A: normal diet; B: high-cholesterol diet; C: high-cholesterol diet + L. plantarum 9-41-
A; D: high-cholesterol diet+ L. fermentum M1-16. All the photomicrographs show HE staining (original magnification × 400).
Table 3 Degrees of liver lipid deposition
Group Degree of fatty deposition* (n = 10 per group)
- + ++ +++
Control 10 0 0 0
Model 0 6 4 0
L.9-41-A 8 2 0 0
L.M1-16 7 2 1 0
Control group: normal diet; model group: high-cholesterol diet; L.9-41-A
group: high-cholesterol diet + L. plantarum 9-41-A; L.M1-16 group: high-
cholesterol diet+ L. fermentum M1-16.
*Standard of classification and score for the degree of lipid deposition: +, mild
fatty degeneration, fatty hepatocytes occupy 30-50% of the hepatic
parenchyma; ++, moderate fatty degeneration, fatty hepatocytes occupy 50-
75% of the hepatic parenchyma; +++, severe fatty degeneration, fatty
hepatocytes occupy > 75% of the hepatic parenchyma.
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Page 6 of 11in vivo. Supplementation with either of the two strains
was effective in reducing serum cholesterol, LDL-C and
TG concentrations in rats compared to those fed the
same high-cholesterol diet but without LAB supplemen-
tation. In particular, these effects were more evident with
L. plantarum 9-41-A (TCH, TG and liver cholesterol
reduced by 25.3%, 16.9% and 22.3%, respectively). Our
results confirm those described in previous reports
[6,21,25]. However, there are also differing reports for
Lactobacillus rhamnosus, L. fermentum and Lactobacillus
acidophilus [19,20,26]. These conflicting findings could
be explained by confounding variables, such as different
sources and properties of LAB strains, varying clinical
characteristics of the subjects, LAB doses, and lengths of
treatment[21,27].
LDL-C is the main component of serum cholesterol.
Therefore, lowering of the LDL-C level may be an impor-
tant factor for reducing serum total cholesterol. Our two
LAB strains reduced the higher serum LDL-C concentra-
tions in rats caused by the high-cholesterol diet com-
pared with the model group. Park et al. [28] had reported
that the hepatic LDL-R mRNA expression of rats fed on
either a normal diet or a high-cholesterol diet increased
with L. acidophilus ATCC 43121 supplementation and
Figure 3 Adipocytes in WAT sections in the four groups. A: normal diet; B:high-cholesterol diet; C: high-cholesterol diet + L. plantarum 9-41-
A; D: high-cholesterol diet + L. fermentum M1-16. All the photomicrographs show HE staining (original magnification × 400).
Table 4 Adipocyte number and size in the WAT under each field (n = 10 per group)
Group Number/HP Major axis (μm) Minor axis (μm) Diameter (μm)
Control 56.4
a ± 4.2 36.6
b ± 3.6 31.5
b ± 3.2 33.8
b ± 3.3
Model 27.5
c ± 4.3 55.2
a ± 4.4 49.19
a ± 5.6 52.2
a ± 5.0
L.9-41-A 50.3
a ± 5.7 39.4
b ± 3.9 36.7
b ± 2.3 38.0
b ± 3.0
L.M1-16 39.1
b ± 6.3 51.9
a ± 7.3 43.75
a ± 5.9 47.8
a ± 6.6
Control group: normal diet; model group: high-cholesterol diet; L.9-41-A group: high-cholesterol diet + L. plantarum 9-41-A; L.M1-16 group: high-cholesterol diet
+ L. fermentum M1-16.
Diameter = (major axis+minor axis)/2.
The data are shown as the mean ± standard deviation.
a,b,c Mean values within a column with different superscript letters differ significantly (p < 0.05, n = 10).
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Page 7 of 11the serum LDL-C level reduced accordingly, but by what
means the LAB affect the hepatic LDL-R mRNA expres-
sion needs to be investigated furtherly. The two strains
did not appear to affect HDL-C concentrations. Ibrahim
et al. [29] and St-Onge et al. [30] reported similar results
about the influence of fermented milk on the HDL-C
level in rats or humans. However, Hashimoto et al. [31]
found that a diet containing Lactobacillus casei TMC
0409 could increase the concentration of HDL-C in rats.
Shin et al. [32] also recently reported that the serum
HDL-C levels in rats were increased by sonication-killed
Bifidobacterium longum. A convincing explanation for
these controversial findings remains unclear, although
different properties of the bacterial strains could be con-
sidered. We also found that the TCH/HDL-C and TG/
HDL-C ratios, which are highly independent predictors
of CVD [33,34], were reduced in rats supplemented with
LAB. Further studies are necessary to confirm these
observations, and thereby more definitively predict
whether LAB supplementation does reduce the risk of
CVD.
As expected, we confirmed that the high-cholesterol
diet increased hepatic cholesterol and TG content in
rats. Rats supplemented with L. plantarum 9-41-A and
L. fermentum M1-16 displayed significant reductions in
hepatic cholesterol and TG levels and lipid deposition.
Figure 4 Populations of E. coli, Enterococcus faecalis,
Lactobacillus, and Bifidobacterium in rat cecums in the four
groups. Control group: normal diet; model group: high-cholesterol
diet; L.9-41-A group: high-cholesterol diet + L. plantarum 9-41-A; L.
M1-16 group: high-cholesterol diet + L. fermentum M1-16. a: Counts
of E. coli colonies. b: Counts of Enterococcus faecalis colonies. c:
Counts of Lactobacillus colonies. d: Counts of Bifidobacterium
colonies.
a,b,c Mean values with different superscript letters differ
significantly (p < 0.05).
Figure 5 Fecal water content from the rats in the four groups.
Control group: nomal diet; model group:high-cholesterol diet; L.9-
41-A group:high-cholesterol diet + L. plantarum 9-41-A; L.M1-16
group:high-cholesterol diet + L. fermentum M1-16. a:Water content
on the middleday of the third week. b:Water content on the
middleday of the sixth week.
a,b Mean values with different
superscript letters differ significantly (p < 0.05).
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and TG levles in LAB-treated rats were actually reduced,
rather than merely being redistributed from the blood to
the liver. The lower level of hepatic cholesterol and TG
content could decrease the conversion of IDL to LDL-C
particles, and result in the decrease of serum LDL-C
concentration, that might be another reason for the
effects of our two strains to lower LDL-C level.
It has been reported that certain probiotic strains
could enhance fecal elimination of bile acids and this
may alter the cholesterol synthesis pathways and
resulted in a decrease of serum cholesterol concentra-
tion [28]. We found more bile acids in the feces of the
LAB-treated rats, especially in those rats in the L.9-41-A
group. Therefore, one possible mechanism for how our
two strains lowered the cholesterol levels may be that
more bile acids in the enterohepatic circulation were
deconjugated and precipitated, and excreted from the
feces, resulting in reduced serum cholesterol concentra-
tions. This may partly explain that why rats in the L.9-
41-A group had lower serum cholesterol level than rats
in the L.M1-16 group. In addition, more fecal choles-
terol was detected in the L.9-41-A and L.M1-16 group
rats. LAB may assimilate dietary cholesterol by incorpor-
ating it into their cellular membranes or cell walls, and
then via fecal excretion [35]. Thus, LAB strains with
hypocholesterolemic properties may lower serum cho-
lesterol in multiple ways.
Generally, a high-cholesterol diet could increase the
body weight. To the best of our knowledge, only a few
studies have reported a weight-lowering effect of LAB
besides a hypocholesterolemic ability. We observed sig-
nificant weight loss (p < 0.05) in the rats supplemented
with L. plantarum 9-41-A compared with the model
group rats, and decreased liver and adipose tissue weight
contributed to this finding. In addition, adipocytes of the
mesenteric WAT in the L.9-41-A rats were smaller than
those in the model group rats. Some bacterial strains
are considered to have preventive effects on excessive
body weight gain[22,36,37]. Fat digestion and absorption
in the small intestine may be affected by the gut micro-
biota. Hamad et al. [36] reported a reduction in the adi-
pocyte size of rats treated with fermented skimmed milk
containing Lactobacillus gasseri SBT2055. The authors
therefore considered that the skimmed milk fermented
by L. gasseri SBT2055 would reduce fat storage through
the inhibition of dietary fat absorption. Increased bile
acid excretion in the feces could elevate bile acid synth-
esis, and this process may also contribute to the
observed weight-lowering effect. Ikemoto et al. [38]
found that cholate could inhibit diet-induced obesity by
decreasing acyl-CoA synthetase mRNA expression.
Watanabe et al. [39] also reported that bile acids could
induce energy expenditure. Nevertheless, additional
research on the mechanisms behind these actions is
required.
Gut microbiota distortions may potentially contribute to
a wide range of diseases. Effective interventions in the gut
microbiota composition with probiotic supplementation
may improve health and prevent the onset of certain dis-
eases[40]. Analyses of the rat intestinal microflora demon-
strated that E. coli was increased while Lactobacillus and
Bifidobacterium were decreased in the model group,
implying that the high-cholesterol diet may have interfered
with the intestinal microbiota. Stepankova et al. [41] found
that absence of gut microbiota (germ-free conditions)
accelerates the atherosclerosis in apoE-deficient mice,
which also indicates the existance of the relationship
between intestinal microbiota and serum cholesterol
levels. Here we presume that LAB may have successfully
ameliorated the intestinal microbiota disorder induced by
a high-cholesterol diet and exerting a beneficial effect that
influenced lipid profiles. The exact mechanism in vivo
need be studied further to verify our presumption. Certain
LAB strains have been shown to inhibit the proliferation
of pathogenic bacteria [42,43]. In our study, L. plantarum
9-41-A and L. fermentum M1-16 inhibited the growth of
E. coli; in addition, the numbers of Lactobacillus and Bifi-
dobacterium were significantly higher in the LAB-treated
rats, suggesting that the two strains used can successfully
tolerate gastric acid and bile salts, then benefit the prolif-
eration of Lactobacillus and Bifidobacterium which are
considered benefical to humans. Imbalances in the gut
microflora could be considered to be environmental fac-
tors involved in the development of obesity and its asso-
ciated metabolic disorders [44-46]. Modulation of the
intestinal microbiota by supplementation with certain
LAB strains may lead to body weight reduction.
By detecting the fecal water content of all rats we
found that L. plantarum 9-41-A and L. fermentum M1-
16 increased the fecal water content in rats. Since the
fecal water content can be used as an index of fecal
elimination, our observations suggest that these two
LAB strains have laxative potential and may stimulate
bowel movements. Consequently, the transit time for
cholesterol absorption in the intestine might also be
reduced. This could be another explanation for the cho-
lesterol-lowering ability of LAB strains.
Our study had some limitations, we only used Sprague-
Dawley rats, and therefore, we cannot deny that the effects
of LAB on cholesterol may be specific for this particular
strain, and not general. So before a definite conclusion
about the hypocholesterolemic effects of our lactobacilli
can be reached, at least one to two more animal models
require testing. Besides, Chinese people are mainly on a
eastern dietaty pattern which includes wheat, rice, vegeta-
bles and fruits. Since diet can play a role in the composi-
tion and metabolic characteristics of microbiota residented
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strains in our present study which were isolated from the
stool of healthy adult Chinese volunteers might be more
suitable for the future application on Asian people who
are mainly on a eastern dietatyp a t t e r n ,m o r ei n t e n s i v e
researchs should be conducted to prove this presumption.
Conclusions
In summary, fecal-derived L. plantarum 9-41-A and L. fer-
mentum M1-16 exerted significant hypocholesterolemic
effect on Sprague-Dawley rats fed a high-cholesterol diet,
with the former strain trending towards more significant
reductive effects. Accordingly, the L.9-41-A strain resulted
in more significant body weight loss and lower fat storage.
The two strains are also able to contribute to a healthier
intestinal microbial banlance. These findings indicate that
the effects of LAB on lipid metabolism may differ among
strains, and that a search for more potent and better bac-
terial strains was meaningful. The L. plantarum 9-41-A
strain may represent a potential therapeutic agent for con-
trolling hyperlipidemia and lessening excessive body weight
gain. The mechanisms behind these effects are likely to be
diverse and will require further investigations in vivo.
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